VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
ABSIAbsci Corporation
$7.41$1.2B
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist

ABSI logoAbsci Corporation(ABSI)Earnings, Financials & Key Ratios

ABSI•NASDAQ
Price updated Jun 19, 2026
SectorHealthcareIndustryBiotechnologySub-IndustryDrug Discovery and Antibody Platforms
AboutAbsci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.Show more
  • Revenue$3M-38.2%
  • EBITDA-$113M-18.3%
  • Net Income-$115M-11.7%
  • EPS (Diluted)-0.84+10.6%
  • Gross Margin-319.36%+75.0%
  • EBITDA Margin-4034.86%-91.6%
  • Operating Margin-4454.21%-85.5%
  • Net Margin-4113.68%-80.9%
  • ROE-62.5%-7.7%

ABSI Key Insights

Absci Corporation (ABSI) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

  • ✓Company is almost debt free
  • ✓Momentum leader: RS Rating 97 (top 3%)

✗Weaknesses

  • ✗Profits declining 51.7% over 5 years
  • ✗Negative free cash flow
  • ✗Sales declining 10.1% over 5 years
  • ✗Shares diluted 24.1% in last year
  • ✗Low asset turnover indicates capital-intensive operations

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Get notified when ABSI posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

ABSI Price & Volume

Absci Corporation (ABSI) stock price & volume — 10-year historical chart

Loading chart...

ABSI Growth Metrics

Absci Corporation (ABSI) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-
5 Years-10.14%
3 Years-21.31%
TTM-61.87%

Profit CAGR

10 Years-
5 Years-
3 Years-
TTM-10.2%

EPS CAGR

10 Years-
5 Years-
3 Years-
TTM9.78%

Return on Capital

10 Years-43.31%
5 Years-47.17%
3 Years-57.54%
Last Year-65.9%

ABSI Recent Earnings

Absci Corporation (ABSI) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat EPS 2/12 qtrs (17%)●Beat Revenue 1/12 qtrs (8%)
Q2 2026Latest
May 7, 2026
Metric
Actual
Est
EPS
$0.19+5.0%
$0.20
Rev
$215,000-82.9%
$1M
Q2 2026
Mar 24, 2026
Metric
Actual
Est
EPS
$0.23-43.8%
$0.16
Rev
$650,000-51.5%
$1M
Q4 2025
Nov 12, 2025
Metric
Actual
Est
EPS
$0.20-5.3%
$0.19
Rev
$378,000-72.6%
$1M
Q3 2025
Aug 12, 2025
Metric
Actual
Est
EPS
$0.24-26.3%
$0.19
Rev
$593,000-88.5%
$5M
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q2 2026LatestMay 7, 2026
$0.19vs $0.20+5.0%
$215,000vs $1M-82.9%
Q2 2026Mar 24, 2026
$0.23vs $0.16-43.8%
$650,000vs $1M-51.5%
Q4 2025Nov 12, 2025
$0.20vs $0.19-5.3%
$378,000vs $1M-72.6%
Q3 2025Aug 12, 2025
$0.24vs $0.19-26.3%
$593,000vs $5M-88.5%
Based on last 12 quarters of dataView full earnings history →

ABSI Peer Comparison

Absci Corporation (ABSI) competitors in Drug Discovery and Antibody Platforms — business model, growth, and fundamentals comparison

Select Columns
Stock Universe
Valuation
Growth
Profitability
Financial Health
Dividends & Buybacks
Price Performance
Technical
Fundamentals ($)
Sector-Specific
Institutional Holdings
CompanyMarket CapStock PriceP/E Ratio (TTM)Revenue Growth 1YNet MarginReturn on Equity (ROE)FCF YieldDebt / Equity
RXRX logoRXRXRecursion Pharmaceuticals, Inc.Direct Competitor1.44B3.23-2.2426.92%-8.44%-54.32%0.07
SDGR logoSDGRSchrödinger, Inc.Direct Competitor1.18B15.76-11.1823.29%-40.6%-30.85%0.30
ALIT logoALITAlight, Inc.Direct Competitor298.32M0.57-0.10-3%-137.5%-171.72%1.92
TWST logoTWSTTwist Bioscience CorporationProduct Competitor5.45B87.56-67.3520.32%-19.85%-17.46%0.29
BEAM logoBEAMBeam Therapeutics Inc.Product Competitor3.51B34.14-42.15120.01%-49.17%-5.89%0.24
NTLA logoNTLAIntellia Therapeutics, Inc.Product Competitor1.76B15.67-4.1116.92%-5.97%-57.27%0.14
CRSP logoCRSPCRISPR Therapeutics AGProduct Competitor5.22B54.09-8.36-89.97%-138.57%-30.88%0.21
ILMN logoILMNIllumina, Inc.Supply Chain24.6B161.9329.71-0.78%19.43%32.84%0.94

Compare ABSI vs Peers

Absci Corporation (ABSI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs RXRX

Most directly comparable listed peer for ABSI.

Scale Benchmark

vs TMO

Larger-name benchmark to compare ABSI against a more recognizable public peer.

Peer Set

Compare Top 5

vs RXRX, SDGR, ALIT, TWST

ABSI Income Statement

Absci Corporation (ABSI) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily
MetricDec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25TTM
Sales/Revenue
2.06M4.78M4.78M5.75M5.72M4.53M2.8M1.84M
Revenue Growth %
-132.04%0.04%20.18%-0.5%-20.71%-38.24%-61.87%
Cost of Goods Sold
011.45M44.59M58.91M47.57M62.46M11.74M26.01M
COGS % of Revenue
-239.5%932.37%1025.02%831.88%1377.57%419.36%-
Gross Profit
2.06M▲ 0%
-6.67M▼ 423.7%
-39.8M▼ 496.9%
-53.16M▼ 33.6%
-41.85M▲ 21.3%
-57.92M▼ 38.4%
-8.94M▲ 84.6%
-24.18M▲ 0%
Gross Margin %
100%-139.5%-832.37%-925.02%-731.88%-1277.57%-319.36%-1316.88%
Gross Profit Growth %
--423.69%-496.94%-33.56%21.28%-38.41%84.56%-
Operating Expenses
8.32M6.63M35.43M53.59M73.67M50.96M115.78M104.36M
OpEx % of Revenue
404.13%138.77%740.99%932.47%1288.32%1124.02%4134.86%-
Selling, General & Admin
3.52M5.5M000035.06M17.68M
SG&A % of Revenue
171.02%115.1%----1252.07%-
Research & Development
4.31M11.45M44.59M58.91M48.07M63.86M81.42M84.33M
R&D % of Revenue
209.27%239.5%932.37%1025.02%840.63%1408.45%2907.79%-
Other Operating Expenses
491K-10.32M-9.15M-5.32M25.6M-12.9M-700K0
Operating Income
-6.26M▲ 0%
-13.3M▼ 112.3%
-75.24M▼ 465.7%
-106.75M▼ 41.9%
-115.52M▼ 8.2%
-108.89M▲ 5.7%
-124.72M▼ 14.5%
-128.53M▲ 0%
Operating Margin %
-304.13%-278.26%-1573.36%-1857.49%-2020.2%-2401.59%-4454.21%-7000.82%
Operating Income Growth %
--112.31%-465.66%-41.88%-8.21%5.74%-14.54%-
EBITDA
-5.77M-12.17M-68.58M-93.71M-101.52M-95.5M-112.98M-117.14M
EBITDA Margin %
-280.29%-254.6%-1434.21%-1630.64%-1775.38%-2106.29%-4034.86%-6380.01%
EBITDA Growth %
--110.77%-463.55%-36.64%-8.33%5.93%-18.3%-17.05%
D&A (Non-Cash Add-back)
491K1.13M6.65M13.04M14M13.39M11.74M11.4M
EBIT
-6.32M-13.72M-74.34M-106.75M-93.68M-107.49M-124.72M-126.94M
Net Interest Income
-268K-634K-3.43M-972K-1.01M-565K-209K-112K
Interest Income
00000000
Interest Expense
268K634K3.43M972K1.01M565K209K112K
Other Income/Expense
-319K-1.05M-34.62M1.39M5.05M5.85M9.6M10.19M
Pretax Income
-6.58M▲ 0%
-14.35M▼ 118.0%
-109.86M▼ 665.4%
-105.36M▲ 4.1%
-110.47M▼ 4.8%
-103.04M▲ 6.7%
-115.11M▼ 11.7%
-118.34M▲ 0%
Pretax Margin %
-319.61%-300.27%-2297.34%-1833.39%-1931.9%-2272.52%-4111.21%-6445.81%
Income Tax
00-8.9M-461K100K70K69K91K
Effective Tax Rate %
0%0%8.1%0.44%-0.09%-0.07%-0.06%-0.08%
Net Income
-6.58M▲ 0%
-14.35M▼ 118.0%
-100.96M▼ 603.4%
-104.9M▼ 3.9%
-110.57M▼ 5.4%
-103.11M▲ 6.7%
-115.18M▼ 11.7%
-118.44M▲ 0%
Net Margin %
-319.61%-300.27%-2111.25%-1825.37%-1933.65%-2274.06%-4113.68%-6450.76%
Net Income Growth %
--118%-603.41%-3.91%-5.4%6.75%-11.71%-10.2%
Net Income (Continuing)
-6.58M-14.35M-100.96M-104.9M-110.57M-103.11M-115.18M-118.44M
Discontinued Operations
00000000
Minority Interest
00000000
EPS (Diluted)
-0.07▲ 0%
-0.54▼ 632.7%
-1.11▼ 105.6%
-1.15▼ 3.6%
-1.20▼ 4.3%
-0.94▲ 21.7%
-0.84▲ 10.6%
-0.77▲ 0%
EPS Growth %
--632.7%-105.56%-3.6%-4.35%21.67%10.64%9.78%
EPS (Basic)
-0.07-0.54-1.11-1.15-1.20-0.94-0.84-
Diluted Shares Outstanding
92.25M92.25M92.65M90.85M92.03M110.24M136.78M152.96M
Basic Shares Outstanding
92.25M92.25M92.65M90.85M92.03M110.24M136.78M152.96M
Dividend Payout Ratio
--------

ABSI Balance Sheet

Absci Corporation (ABSI) balance sheet — assets, liabilities & shareholders' equity

MetricDec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25TTM
Total Current Assets
13.65M73.23M273.08M186.86M120.58M133.83M149.57M131.97M
Cash & Short-Term Investments
13.09M69.87M252.57M164.43M97.66M112.42M144.29M125.7M
Cash Only
13.09M69.87M252.57M59.95M72.36M41.21M20.02M8.63M
Short-Term Investments
000104.48M25.3M71.21M124.27M117.08M
Accounts Receivable
222K1.59M1.43M1.55M2.19M000
Days Sales Outstanding
39.34121.72108.7798.44139.73--84.49
Inventory
0010.51M15.02M0000
Days Inventory Outstanding
--86.0693.08----
Other Current Assets
000020.73M21.41M5.28M6.27M
Total Non-Current Assets
5.82M15.34M153.12M134.15M96.72M79.78M66.72M63.62M
Property, Plant & Equipment
5.01M13.38M58.65M58.04M45.82M33.13M23.77M21.41M
Fixed Asset Turnover
0.41x0.36x0.08x0.10x0.12x0.14x0.12x0.07x
Goodwill
0021.34M21.34M0000
Intangible Assets
283K054.99M51.62M48.25M44.88M41.51M40.77M
Long-Term Investments
790K016.84M1.86M0002.12M
Other Non-Current Assets
531K1.95M18.14M-16.38M2.65M1.76M1.44M383K
Total Assets
19.47M▲ 0%
88.57M▲ 354.9%
426.19M▲ 381.2%
321.01M▼ 24.7%
217.3M▼ 32.3%
213.61M▼ 1.7%
216.3M▲ 1.3%
195.59M▲ 0%
Asset Turnover
0.11x0.05x0.01x0.02x0.03x0.02x0.01x0.01x
Asset Growth %
-354.88%381.2%-24.68%-32.31%-1.7%1.26%-28.31%
Total Current Liabilities
3.47M10.1M33.86M30.27M29.56M28.66M22.77M20.03M
Accounts Payable
268K2.12M8.38M2.41M1.5M3.53M2.76M8.82M
Days Payables Outstanding
-67.4768.6414.9511.5320.6285.6785.49
Short-Term Debt
1.2M1.53M2.4M2.95M3.26M2.73M873K2.27M
Deferred Revenue (Current)
780K01.35M445K3.17M1.12M739K1.19M
Other Current Liabilities
02.63M0012.75M12.75M06.27M
Current Ratio
3.94x7.25x8.07x6.17x4.08x4.67x6.57x6.59x
Quick Ratio
3.94x7.25x7.75x5.68x4.08x4.67x6.57x6.59x
Cash Conversion Cycle
--126.19176.58----1
Total Non-Current Liabilities
57.16M11.47M26.23M16.32M11.56M5.82M4.08M3.59M
Long-Term Debt
1.75M4.14M1.12M7.98M4.66M1.26M00
Capital Lease Obligations
2.38M6.58M12.2M8.07M5.64M4.43M2.62M11.41M
Deferred Tax Liabilities
00743K238K186K000
Other Non-Current Liabilities
53.03M749K12.16M35K109K133K1.02M806K
Total Liabilities
60.63M21.56M60.09M46.59M41.12M34.48M26.85M23.62M
Total Debt
6.02M14.5M20.01M22.98M15.88M10.11M5.3M4.42M
Net Debt
-7.07M-55.37M-232.56M-36.97M-56.48M-31.11M-14.72M-4.21M
Debt / Equity
-0.22x0.05x0.08x0.09x0.06x0.03x0.03x
Debt / EBITDA
--------0.04x
Net Debt / EBITDA
-------0.04x
Interest Coverage
-23.57x-21.64x-21.66x-109.83x-92.75x-190.24x-596.74x-1133.38x
Total Equity
-41.16M▲ 0%
67M▲ 262.8%
366.11M▲ 446.4%
274.41M▼ 25.0%
176.18M▼ 35.8%
179.13M▲ 1.7%
189.45M▲ 5.8%
171.97M▲ 0%
Equity Growth %
-262.8%446.39%-25.05%-35.8%1.68%5.76%-24.99%
Book Value per Share
-0.450.733.953.021.911.621.391.12
Total Shareholders' Equity
-41.16M67M366.11M274.41M176.18M179.13M189.45M171.97M
Common Stock
2K2K9K9K9K12K15K15K
Retained Earnings
-41.38M-90.06M-191.03M-295.93M-406.5M-509.6M-624.78M-654.38M
Treasury Stock
00000000
Accumulated OCI
-52.76M0-13K-120K-37K-4K591K304K
Minority Interest
00000000

ABSI Cash Flow Statement

Absci Corporation (ABSI) cash flow — operating, investing & free cash flow history

MetricDec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25TTM
Cash from Operations
-6.03M-10.97M-60.6M-81.34M-64.64M-72.4M-92.92M-97.39M
Operating CF Margin %
-292.82%-229.5%-1267.21%-1415.33%-1130.4%-1596.87%-3318.75%-
Operating CF Growth %
--81.86%-452.4%-34.23%20.54%-12.02%-28.35%-113.4%
Net Income
-6.58M-14.35M-100.96M-104.9M-110.57M-103.11M-115.18M-118.44M
Depreciation & Amortization
491K1.13M6.65M13.1M14M13.39M11.74M11.4M
Stock-Based Compensation
42K420K10.61M12.54M11.42M19.45M18.32M13.53M
Deferred Taxes
00-8.9M-505K-52K000
Other Non-Cash Items
108K824K35.15M-30K19.05M-1.77M-8.23M-3.97M
Working Capital Changes
-89K1.01M-3.15M-1.54M1.52M-368K423K81K
Change in Receivables
-102K-1.37M230K-148K-666K2.24M01.38M
Change in Inventory
00000000
Change in Payables
82K903K1.57M-533K-786K2.03M1.09M-2.17M
Cash from Investing
-1.09M-2.17M-67.38M-126.98M81.94M-41.58M-50.16M-27.75M
Capital Expenditures
-1.1M-2.18M-38.05M-16.18M-860K-404K-1.11M-1.11M
CapEx % of Revenue
53.3%45.63%795.63%281.45%15.04%8.91%39.54%60.57%
Acquisitions
00-28.13M-8M001.31M1.2M
Investments
--------
Other Investing
9K10K0783K254K939K00
Cash from Financing
12.71M70.97M336.19M5.24M-4.48M82.53M105.95M70.71M
Debt Issued (Net)
2.38M1.64M120.85M4.58M-5.34M-4.03M-3.2M-2.85M
Equity Issued (Net)
10.33M69.33M215.34M656K862K86.56M109.14M73.56M
Dividends Paid
00000000
Share Repurchases
00000000
Other Financing
00000000
Net Change in Cash
5.58M▲ 0%
57.83M▲ 935.5%
208.22M▲ 260.0%
-203.08M▼ 197.5%
12.82M▲ 106.3%
-31.45M▼ 345.2%
-37.14M▼ 18.1%
-54.44M▲ 0%
Free Cash Flow
-7.13M▲ 0%
-13.15M▼ 84.4%
-98.64M▼ 650.1%
-97.51M▲ 1.1%
-65.5M▲ 32.8%
-72.81M▼ 11.2%
-94.03M▼ 29.2%
-98.5M▲ 0%
FCF Margin %
-346.12%-275.13%-2062.84%-1696.78%-1145.44%-1605.78%-3358.29%-5365.2%
FCF Growth %
--84.45%-650.09%1.15%32.83%-11.16%-29.15%-28.25%
FCF per Share
-0.08-0.14-1.06-1.07-0.71-0.66-0.69-0.64
FCF Conversion (FCF/Net Income)
0.92x0.76x0.60x0.78x0.58x0.70x0.81x0.83x
Interest Paid
202K508K652K895K970K561K00
Taxes Paid
00000000

ABSI Key Ratios

Absci Corporation (ABSI) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric202020212022202320242025TTM
Return on Equity (ROE)
-111.07%-46.62%-32.76%-49.08%-58.04%-62.5%-63.58%
Return on Invested Capital (ROIC)
--77.73%-43.16%-48.52%-61.01%-57.96%-55.7%
Gross Margin
-139.5%-832.37%-925.02%-731.88%-1277.57%-319.36%-1316.88%
Net Margin
-300.27%-2111.25%-1825.37%-1933.65%-2274.06%-4113.68%-6450.76%
Debt / Equity
0.22x0.05x0.08x0.09x0.06x0.03x0.03x
Interest Coverage
-21.64x-21.66x-109.83x-92.75x-190.24x-596.74x-1133.38x
FCF Conversion
0.76x0.60x0.78x0.58x0.70x0.81x0.83x
Revenue Growth
132.04%0.04%20.18%-0.5%-20.71%-38.24%-61.87%
Related:ABSI Dividend History·ABSI Revenue History·ABSI Price History·ABSI P/E History·ABSI Financial Ratios·ABSI Institutional Holders

ABSI SEC Filings & Documents

Absci Corporation (ABSI) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

May 7, 2026·SEC

Material company update

Mar 24, 2026·SEC

Material company update

Mar 6, 2026·SEC

10-K Annual Reports

4
FY 2026

Mar 24, 2026·SEC

FY 2025

Mar 18, 2025·SEC

FY 2024

Mar 21, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

May 7, 2026·SEC

FY 2025

Nov 12, 2025·SEC

FY 2025

Aug 12, 2025·SEC

ABSI Frequently Asked Questions

Absci Corporation (ABSI) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Absci Corporation (ABSI) reported $1.8M in revenue for fiscal year 2025. This represents a 11% decrease from $2.1M in 2019.

Absci Corporation (ABSI) saw revenue decline by 38.2% over the past year.

Absci Corporation (ABSI) reported a net loss of $118.4M for fiscal year 2025.

Dividend & Returns

Absci Corporation (ABSI) has a return on equity (ROE) of -62.5%. Negative ROE indicates the company is unprofitable.

Absci Corporation (ABSI) had negative free cash flow of $98.5M in fiscal year 2025, likely due to heavy capital investments.

What if you invested $1,000 in ABSI back in 2019?

Total return calculator · dividends reinvested · 7+ years of data

See returns →

How much would $100/month in ABSI be worth today?

Dollar cost averaging calculator · DCA vs lump sum

Calculate →